Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

SAB Biotherapeutics Inc

Healthcare US SABS

3.38USD
-0.09(2.59%)

Last update at 2026-06-05T20:00:00Z

Day Range

3.283.47
LowHigh

52 Week Range

2.3610.50
LowHigh

Fundamentals

  • Previous Close 3.47
  • Market Cap25.10M
  • Volume351021
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-37.34619M
  • Revenue TTM2.60M
  • Revenue Per Share TTM0.40
  • Gross Profit TTM -12.53433M
  • Diluted EPS TTM-6.72

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -18.71517M -17.14453M 20.12M -8.98629M
Minority interest - - - -
Net income -18.74080M -17.44448M 20.12M -9.41736M
Selling general administrative 16.38M 17.09M 6.77M 4.10M
Selling and marketing expenses - - - -
Gross profit 23.90M 60.88M 55.24M 3.44M
Reconciled depreciation 1.65M 1.65M 0.55M 0.32M
Ebit -28.91762M -13.39320M 20.56M -8.67354M
Ebitda -27.15919M -11.71100M 21.14M -8.23441M
Depreciation and amortization 1.76M 1.68M 0.58M 0.44M
Non operating income net other 10.50M -3.45687M - -
Operating income -28.91762M -13.39320M 20.56M -8.67354M
Other operating expenses 28.92M 13.39M 34.68M 12.12M
Interest expense 0.30M 0.29M 0.47M 0.43M
Tax provision 0.03M - - -
Interest income 0.07M 0.02M 0.03M 0.11M
Net interest income -0.23051M -0.27134M -0.44302M -0.31534M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.03M 0.30M 0.47M 0.43M
Total revenue 23.90M 60.88M 55.24M 3.44M
Total operating expenses 28.92M 13.39M 34.68M 12.12M
Cost of revenue - - - -
Total other income expense net 10.20M -3.75133M -0.43902M -0.31275M
Discontinued operations - - - -
Net income from continuing ops -18.74080M -17.14453M 20.12M -8.98629M
Net income applicable to common shares -18.74080M -17.14453M 12.98M -8.98629M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 83.94M 50.90M 79.37M 56.54M 18.00M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.34M 1.49M 7.20M 1.28M 0.12M
Total liab 26.64M 19.85M 40.82M 17.53M 20.31M
Total stockholder equity 57.30M 31.06M 38.55M 39.01M -2.30557M
Deferred long term liab - 0.32M 10.72M - -
Other current liab 6.69M 9.92M 18.80M 1.92M 0.50M
Common stock 0.00093M 0.00509M 0.00435M 0.00352M 0.00352M
Capital stock 0.00093M 0.00509M 0.00435M 0.00558M 0.00496M
Retained earnings -90.06354M -47.86975M -29.12895M -11.98442M -32.10219M
Other liab - 0.32M 10.72M - -
Good will - - - - -
Other assets - 0.47M 35.54M - -
Cash 56.57M 15.05M 33.21M 12.61M 6.35M
Cash and equivalents - - - - -
Total current liabilities 10.81M 14.99M 24.68M 11.06M 4.62M
Current deferred revenue 1.32M - 0.10M 0.10M -
Net debt -50.65901M -9.11814M -26.46262M -4.48430M 1.29M
Short term debt 1.85M 1.40M 1.33M 1.66M 1.95M
Short long term debt 1.05M 0.77M 0.03M 0.54M 1.39M
Short long term debt total 5.91M 5.93M 6.74M 8.13M 7.64M
Other stockholder equity 147.34M 78.92M 67.67M 50.99M 29.79M
Property plant equipment - 23.25M 30.95M 22.08M 8.71M
Total current assets 58.91M 22.10M 48.42M 34.46M 9.29M
Long term investments - - - - -
Net tangible assets - 31.06M 38.55M 39.01M -2.30701M
Short term investments - - - - -
Net receivables 0.00000M 5.56M 8.01M 20.57M 2.82M
Long term debt - 0.54M - 0.17M 0.05M
Inventory - - - - -
Accounts payable 0.95M 3.68M 4.46M 7.38M 2.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.03M - - - -
Additional paid in capital - - - - -
Common stock total equity - 0.00509M 0.00435M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -47.86975M -29.12895M - -
Treasury stock - -5.52125M - - -
Accumulated amortization - - - - -
Non currrent assets other 0.35M 0.47M 6.63M - -
Deferred long term asset charges - - - - -
Non current assets total 25.03M 28.81M 30.95M 22.08M 8.71M
Capital lease obligations 4.86M 4.61M 6.72M 7.42M 6.19M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -10.94366M -10.94366M -12.72270M -0.60875M
Change to liabilities -3.41970M -2.93552M 5.31M 1.56M
Total cashflows from investing activities -2.09002M -10.94366M -12.72270M -0.60875M
Net borrowings -1.02406M -0.22727M -0.91788M -0.62327M
Total cash from financing activities 34.12M 34.12M 8.98M 3.68M
Change to operating activities -1.81228M 3.83M 0.48M 0.08M
Net income -17.14453M -17.14453M 20.12M -8.98629M
Change in cash 26.93M 26.93M 6.26M -6.14156M
Begin period cash flow 12.61M 12.61M 6.35M 12.49M
End period cash flow 39.55M 39.55M 12.61M 6.35M
Total cash from operating activities 3.76M 3.76M 10.00M -9.21444M
Issuance of capital stock 7.68M 0.00000M 9.90M 4.30M
Depreciation 1.65M 1.65M 0.55M 0.32M
Other cashflows from investing activities 0.08M - - -
Dividends paid - - - -
Change to inventory - - 0.48M -
Change to account receivables 12.56M 12.56M -17.75076M -2.56291M
Sale purchase of stock -5.52125M 0.00675M - -
Other cashflows from financing activities 39.79M 34.35M 10.56M 4.30M
Change to netincome -7.74080M 5.79M 1.29M 0.37M
Capital expenditures 10.94M 10.94M 12.73M 0.61M
Change receivables 2.45M 12.56M - -
Cash flows other operating 0.82M 0.61M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -24.49812M 26.93M - -
Change in working capital 13.45M 13.45M -11.95433M -0.92337M
Stock based compensation 2.31M 2.31M 1.30M 0.37M
Other non cash items 3.48M 3.48M -0.00000M 0.00000M
Free cash flow -7.18507M -7.18507M -2.72691M -9.82319M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SABS
SAB Biotherapeutics Inc		 -0.09 2.59% 3.38 - - 19.26 0.75 1.21 0.20
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

SAB Biotherapeutics Inc

2100 East 54th Street North, Sioux Falls, SD, United States, 57104

Key Executives

Name Title Year Born
Mr. Samuel J. Reich Exec. Chairman 1975
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, Pres, CEO & Director 1966
Ms. Christine E. Hamilton M.B.A. Co-Founder & Independent Director 1956
Dr. Edward D. Hamilton D.V.M. Co-Founder & Board Observer NA
Mr. Russell P. Beyer C.M.A., M.B.A. Exec. VP & CFO 1955
Dr. Christoph Bausch M.B.A., Ph.D. Exec. VP & COO 1971
Dr. Carlos N. Carillo Ph.D. Sr. VP of Regulatory Affairs NA
Dr. Alexandra Kropotova M.B.A., M.D. Exec. VP & Chief Medical Officer 1972
Mr. Samuel J. Reich CEO & Executive Chairman 1975
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President & Director 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions